DelveInsight business research is a market research and a business consulting firm.
Don't wanna be here? Send us removal request.
Statistics
We looked inside some of the posts by hello-delveinsight and here's what we found interesting.
Average Info
Notes Per Post
0
Likes Per Post
0
Reblog Per Post
0
Reply Per Post
0
Time Between Posts
2 months
Number of Posts By Type
Text
17
Last Seen Tumblr Blogs
Fun Fact
The most popular pages on Tumblr are about Minecraft, GIFs, and David J. Peterson.
Text
DelveInsight's Comprehensive Insights into Parkinson's Disease Market Dynamics
DelveInsight's Parkinson's Disease Market Insights report offers a thorough understanding of current treatment practices, emerging drugs, market share of individual therapies, and the current and forecasted market size from 2019 to 2032. The report provides segmentation for 7MM (the United States, the EU-4 - Italy, Spain, France, and Germany, the United Kingdom, and Japan).
Click here to know Parkinson’s Disease Market
Key Takeaways from the Parkinson's Disease Market Report:
Parkinson's Disease Market Size and Prevalence:
The Parkinson's disease market size in the 7MM was approximately USD 3.2 billion in 2022.
Estimated total diagnosed prevalent Parkinson's disease cases in the 7MM were around 2.5 million in 2022.
Leading Parkinson's Disease Companies and Drug Development:
Key industry leaders, including Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, and others, are actively developing novel Parkinson's disease drugs.
Promising therapies in the pipeline include Tavapadon, P2B001, ABBV-951 (foscarbidopa/foslevodopa), BIIB122/DNL151, and more.
Parkinson's Disease Epidemiological Segmentation:
DelveInsight estimates approximately 2.5 million diagnosed prevalent cases of Parkinson's disease in the 7MM in 2022.
Parkinson's disease is identified as a male-dominant disease, with 54% of cases in males and 46% in females in the 7MM.
Click here to know Parkinson’s Disease Market
Parkinson's Disease Overview:
Parkinson's disease is a degenerative ailment characterized by the loss of nerve cells in the substantia nigra, a brain region governing movement. The exact cause remains unknown, but a combination of genetic and environmental factors is suspected. Motor symptoms such as bradykinesia, stiffness, rest tremor, and postural instability are common, accompanied by non-motor symptoms impacting a patient's quality of life.
Parkinson's Disease Epidemiological Segmentation:
The Parkinson's disease market report offers epidemiological analysis for the study period 2019–2032, segmented into diagnosed prevalent population, gender-specific diagnosed prevalent population, age-specific diagnosed prevalent population, and stage-specific diagnosed prevalent population.
Parkinson's Disease Treatment Landscape:
The Parkinson's Disease treatment landscape involves various drugs, with Levodopa being the gold standard for managing motor problems. Medications such as levodopa, dopamine agonists, MAO B inhibitors, catechol o-methyltransferase inhibitors, and others aim to reduce motor symptoms. INBRIJA (levodopa) is a notable inhalation therapy supplementing daily carbidopa-levodopa medications to alleviate "off-episodes" and motor symptoms.
Pipeline Parkinson's Disease Therapies and Key Companies:
The pipeline includes potential therapies like Tavapadon, P2B001, ABBV-951, BIIB122/DNL151, and others developed by leading companies such as Cerevel Therapeutics, Pfizer, AbbVie, Biogen, and more.
Parkinson's Disease Market Dynamics:
The Parkinson's disease market is anticipated to evolve, driven by research and development efforts, emerging therapies, and improvements in diagnosis rates. However, challenges such as the absence of a cure, symptomatic treatments, side effects, and undetected cases may impede growth. The robust pipeline and advancements in disease-modifying treatments offer optimism for the future.
In conclusion, DelveInsight's Parkinson's Disease Market Insights report provides a comprehensive understanding of the current landscape, promising therapies, and challenges, guiding stakeholders in making informed decisions.
Click here to know Parkinson’s Disease Market
Trending Reports:
Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
Alopecia Market: https://www.delveinsight.com/report-store/alopecia-market
Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
Cerebral Aneurysm Market: https://www.delveinsight.com/report-store/intracranial-aneurysms-market-insight
Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market
Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
Eczema Market: https://www.delveinsight.com/report-store/eczema-market
Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
Bone Grafts And Substitutes Market: https://www.delveinsight.com/report-store/bone-grafts-and-substitutes-market
Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
Healthcare Consulting Service
DelveInsights multidimensional, purposeful, and credible pharma and medtech consulting services will aid in the acceleration of product services, including aspects such as congress intelligence, conference coverage, CI asset/indication tracking, brand presence and penetration assessment, drug therapy uptake, and diagnostic landscape assessment to overcome several market challenges.
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Contact Us:
Ankit Nigam
Assistant Manager Marketing
+91-9650213330
0 notes
Text
Sanfilippo Syndrome Market Report 2032
(Las Vegas, Nevada, USA) DelveInsight’s “Sanfilippo Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Sanfilippo Syndrome, historical and forecasted epidemiology as well as the Sanfilippo Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Sanfilippo Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Sanfilippo Syndrome market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Sanfilippo Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Sanfilippo Syndrome market.
Request for a Free Sample Report @ https://www.delveinsight.com/report-store/sanfilippo-syndrome-market
Some facts of the Sanfilippo Syndrome Market Report are:
According to DelveInsight, Sanfilippo Syndrome market size is expected to grow at a decent CAGR by 2032.
Leading Sanfilippo Syndrome companies working in the market are Amgen Inc, Alkem Labs, LUPIN, Hope Pharmaceuticals, Sanifit, BSN medical, Sun Pharmaceutical Industries Ltd, Seelos Therapeutics, Lysogene, BioMarin Pharmaceutical, Cipla Inc, Mylan N.V. Teva Pharmaceutical Industries Ltd, and Zydus Cadila, and others.
Key Sanfilippo Syndrome Therapies expected to launch in the market are SLS-005, LYS-SAF302, Tralesinidase alfa (BMN-250), and others.
Sanfilippo Syndrome or Mucopolysaccharidosis type III (MPS III), has been classified as a rare disease with an incidence reported to be between 0.28 and 4.1 cases per 100,000 births.
MPS III A is the most common subtype that affects around 1 in 100,000 births.
Sanfilippo syndrome affects males and females equally.
Sanfilippo Syndrome Overview
Sanfilippo syndrome, also known as mucopolysaccharidosis type III (MPS III), is a rare and progressive genetic disorder that affects the metabolism. It belongs to a group of conditions called lysosomal storage disorders. Sanfilippo syndrome is characterized by the deficiency or malfunctioning of enzymes needed to break down complex sugars called glycosaminoglycans (GAGs). As a result, GAGs accumulate in cells throughout the body, leading to cellular dysfunction and organ damage.
There are four subtypes of Sanfilippo syndrome (A, B, C, and D), each caused by a different enzyme deficiency. Symptoms typically appear in early childhood and worsen over time. Common signs include developmental delays, speech impairment, hyperactivity, behavioral problems, sleep disturbances, and eventually, cognitive decline. Physical manifestations may include coarse facial features, enlarged liver and spleen, joint stiffness, and skeletal abnormalities.
Currently, there is no cure for Sanfilippo syndrome. Treatment mainly focuses on managing symptoms and improving the quality of life for affected individuals. This may involve supportive therapies such as physical and occupational therapy, speech therapy, behavioral interventions, and medications to address specific symptoms.
Ongoing research aims to develop potential enzyme replacement therapies, gene therapies, and other innovative approaches to target the underlying cause of Sanfilippo syndrome and provide more effective treatments in the future.
Learn more about Sanfilippo Syndrome treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/sanfilippo-syndrome-market
Sanfilippo Syndrome Market
The Sanfilippo Syndrome market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Sanfilippo Syndrome market trends by analyzing the impact of current Sanfilippo Syndrome therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Sanfilippo Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Sanfilippo Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Sanfilippo Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.
Sanfilippo Syndrome Epidemiology
The Sanfilippo Syndrome epidemiology section provides insights into the historical and current Sanfilippo Syndrome patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Sanfilippo Syndrome market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Sanfilippo Syndrome Epidemiology @ https://www.delveinsight.com/sample-request/sanfilippo-syndrome-market
Sanfilippo Syndrome Drugs Uptake
This section focuses on the uptake rate of the potential Sanfilippo Syndrome drugs recently launched in the Sanfilippo Syndrome market or expected to be launched in 2019-2032. The analysis covers the Sanfilippo Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Sanfilippo Syndrome Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Sanfilippo Syndrome market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Sanfilippo Syndrome Pipeline Development Activities
The Sanfilippo Syndrome report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Sanfilippo Syndrome key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Sanfilippo Syndrome pipeline development activities @ https://www.delveinsight.com/sample-request/sanfilippo-syndrome-market
Sanfilippo Syndrome Therapeutics Assessment
Prominent companies are actively engaged in the Sanfilippo Syndrome Therapeutics market, focusing on the development of innovative treatments. These efforts are expected to fuel the growth of the Sanfilippo Syndrome treatment market in the coming years. Key players in this Sanfilippo Syndrome market include Amgen Inc, Alkem Labs, LUPIN, Hope Pharmaceuticals, Sanifit, BSN medical, Sun Pharmaceutical Industries Ltd, Seelos Therapeutics, Lysogene, BioMarin Pharmaceutical, Cipla Inc, Mylan N.V., Teva Pharmaceutical Industries Ltd, Zydus Cadila, and several others.
Learn more about the emerging Sanfilippo Syndrome therapies & key companies @ https://www.delveinsight.com/sample-request/sanfilippo-syndrome-market
Sanfilippo Syndrome Report Key Insights
1. Sanfilippo Syndrome Patient Population
2. Sanfilippo Syndrome Market Size and Trends
3. Key Cross Competition in the Sanfilippo Syndrome Market
4. Sanfilippo Syndrome Market Dynamics (Key Drivers and Barriers)
5. Sanfilippo Syndrome Market Opportunities
6. Sanfilippo Syndrome Therapeutic Approaches
7. Sanfilippo Syndrome Pipeline Analysis
8. Sanfilippo Syndrome Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Sanfilippo Syndrome Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Sanfilippo Syndrome Competitive Intelligence Analysis
4. Sanfilippo Syndrome Market Overview at a Glance
5. Sanfilippo Syndrome Disease Background and Overview
6. Sanfilippo Syndrome Patient Journey
7. Sanfilippo Syndrome Epidemiology and Patient Population
8. Sanfilippo Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Sanfilippo Syndrome Unmet Needs
10. Key Endpoints of Sanfilippo Syndrome Treatment
11. Sanfilippo Syndrome Marketed Products
12. Sanfilippo Syndrome Emerging Therapies
13. Sanfilippo Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Sanfilippo Syndrome Market Outlook (7 major markets)
16. Sanfilippo Syndrome Access and Reimbursement Overview
17. KOL Views on the Sanfilippo Syndrome Market
18. Sanfilippo Syndrome Market Drivers
19. Sanfilippo Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Contact Us:
Ankit Nigam
+91-9650213330
Other Trending Reports
Foot And Ankle Devices Market | Hepatitis B Virus Market | Image Guided Surgery Devices Market | Bone Anchored Hearing Systems Market | Alopecia Aerata Market | Pressure Ulcers Market Size | Alopecia Areata Market | Brain/cranial Implants Market | Global Electrophysiology Devices Market | Abetalipoproteinemia Market | Alopecia Market | Hearing Aid Devices Market | Hemodynamic Monitoring Systems Market | Neurovascular Devices Market | Parkinson’s Disease Market | Adult Growth Hormone Deficiency Market | Pulse Oximeters Market | Automated External Defibrillators Market | Energy Based Aesthetic Devices Market | Prefilled Syringes Market | Scleroderma Market | Human Papilomavirus Market | Capnography Device Market | Hyperuricemia Market | Atherectomy Devices Market | Xerostomia Market | Defibrillators Market | Blood Glucose Monitoring Systems Market | Acoustic Neuroma Market
0 notes
Text
Acoustic Neuroma Market Growth Anticipated | Oticon Medical, Novartis, Med-El Corporation, Elekta, Natus Medical, Amgen, AstraZeneca, Siemens Healthcare
To strategically aid Acoustic Neuroma companies developing drugs for Acoustic Neuroma, DelveInsight launched a report titled as “Acoustic Neuroma Market Insight Epidemiology and Market Forecast, 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Acoustic Neuroma market.
Get a free sample of “Acoustic Neuroma Market Report”
Acoustic Neuroma Market Report’s Key Highlights:
Acoustic Neuroma market is expected to grow during the study period in 7MM.
Key Acoustic Neuroma Companies: Oticon Medical, Novartis Pharmaceuticals, Med-El Corporation, Elekta, Natus Medical Incorporated, Amgen, AstraZeneca, Siemens Healthcare, and others.
Acoustic Neuroma is estimated to affect 1 in 100,000 people in the general population
Acoustic Neuroma is responsible for 6 in 100 cases of brain tumors
The prevalence of Acoustic Neuroma is more common in middle-aged adults and rare in children
Acoustic Neuroma tends to affect the people aged 30 to 6 and usually has no obvious cases, neither there are any symptoms of cancer in the early stages.
The Acoustic Neuromamarket is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acoustic Neuroma pipeline products will significantly revolutionize the Acoustic Neuroma market dynamics
Acoustic Neuroma Country based Treatment Analysis:
The Acoustic Neuroma treatment market report provides treatment regimen across the 7MM. It will help companies to analyse the practices followed across 7MM, patient journey and advances in Acoustic Neuroma Therapies that have the potential to transform treatment paradigms and improve patient outcomes.
Acoustic Neuroma is a slowly growing non-cancerous tumor that forms along the branches of the eighth cranial nerve. These nerves start from the brain to the inner ear and to other divisions of the body that plays an important role in healing and balancing the body.
If Acoustic Neuroma is diagnosed in the early stages then the tumor can be stopped from further growing, but in case the tumor has already gone bigger than it can cause a life-threatening build-up of fluid in the brain.
Acoustic Neuroma Symptoms:
The symptoms of Acoustic Neuroma includes a gradual loss in hearing, ringing in the affected ear, dizziness, difficulty in balancing, facial numbness and weakness
Download the report to understand which factors are driving Acoustic Neuroma epidemiology trends @ Acoustic Neuroma Epidemiology Forecast
Acoustic Neuroma Epidemiology Insights:
The report proffers historical and forecasted epidemiology insights that helps to understand the target patient population for Acoustic Neuroma. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patient’s pools. The epidemiology in report is segmented as:
Acoustic Neuroma Epidemiology Segmentation:
Total Prevalence of Acoustic Neuroma
Prevalent Cases of Acoustic Neuroma by severity
Gender-specific Prevalence of Acoustic Neuroma
Diagnosed Cases of Episodic and Chronic Acoustic Neuroma
“Assessments as per DelveInsight’s analysts shows that the prevalence of Acoustic Neuroma is more common in middle-aged adults and rare in children”
Acoustic Neuroma Pipeline Therapies:
Nilotinib
Aspirin
Bevacizumab
Gentamicin
Axitinib
Emerging Acoustic Neuroma drugs Uptake:
In June 2023: A clinical trial is expected to initiate with 36 participants to evaluate the efficacy of microsurgical resection of vestibular schwannoma and stereotactic radiosurgery. The trial is sponsored by the Medical College of Wisconsin, United States.
In May 2022: The Brain Foundation, Australia, funded a project led by researchers at the University of Newcastle to develop an innovative target therapy for treating acoustic neuroma.
To know more about Acoustic Neuroma companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/acoustic-neuroma-market
Acoustic Neuroma Market Forecast:
The research includes a thorough analysis of the past and projected markets for Acoustic Neuroma, which includes pharmacological outreach in the 7MM nations.
The dynamics of the Acoustic Neuroma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Bevacizumab, Axitinib, and others during the forecasted period 2019-2032.
Rising prevalence, increasing prevalence, less competition for upcoming therapies and Companies shifting their focus to this area, despite low awareness of the disease are fuelling the Acoustic Neuroma Market.
Discover more about therapies set to grab major Acoustic Neuroma market share @ https://www.delveinsight.com/sample-request/acoustic-neuroma-market
DelveInsight’s report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Acoustic Neuroma market landscape.
Gain Competitive Edge in Indication Market: Understand the current landscape of the Acoustic Neuroma market, including the competitive environment, key companies developing drugs for Acoustic Neuroma, and their strategies. By analyzing Acoustic Neuroma market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
Identify Market Gaps and indication market opportunities: Analysing Acoustic Neuroma epidemiological trends, country wise patient journeys and existing treatment practices can helps in identifying gaps and opportunities within the Acoustic Neuroma market. This involves recognizing areas where current Acoustic Neuroma treatments may be insufficient or where there is an unmet need. The Acoustic Neuroma market report is curated by taking account of various KOLs dealing with Acoustic Neuroma. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific Acoustic Neuroma market needs and price their emerging products strategically to gain a competitive edge.
Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing – reimbursement strategies, partnerships, or other strategic moves. Understanding the Acoustic Neuroma market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
Plan RoadMap to Success : Through this report the leading Acoustic Neuroma companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Acoustic Neuroma market with clarity and purpose.
Related Reports
Parkinson’s Disease Epidemiology Forecast
Parkinson’s Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and Parkinson’s disease epidemiology trends.
Parkinson’s Disease Pipeline
Parkinson’s Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson’s disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others.
Psychosis in Parkinson’s and Alzheimer’s Disease Market
Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson’s and Alzheimer’s disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, among others.
Parkinson’s Disease-Related Dementia Market
Parkinson’s Disease-Related Dementia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease-related dementia companies, including AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., among others.
Other Trending Reports
Foot And Ankle Devices Market | Hepatitis B Virus Market | Image Guided Surgery Devices Market | Bone Anchored Hearing Systems Market | Alopecia Aerata Market | Pressure Ulcers Market Size | Alopecia Areata Market | Brain/cranial Implants Market | Global Electrophysiology Devices Market | Abetalipoproteinemia Market | Alopecia Market | Hearing Aid Devices Market | Hemodynamic Monitoring Systems Market | Neurovascular Devices Market | Parkinson’s Disease Market | Adult Growth Hormone Deficiency Market | Pulse Oximeters Market | Automated External Defibrillators Market | Energy Based Aesthetic Devices Market | Prefilled Syringes Market | Scleroderma Market | Human Papilomavirus Market | Capnography Device Market | Hyperuricemia Market | Atherectomy Devices Market | Xerostomia Market | Defibrillators Market | Blood Glucose Monitoring Systems Market | Acoustic Neuroma Market
Explore Our Success Story on Building an Interactive Competitive Intelligence Dashboard for HR+ HER2- Breast Cancer Market Landscape. Download our Oncology Competitive Intelligence Case study!
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Assistant Manager Marketing
Email: [email protected]
Website: https://www.delveinsight.com/consulting
0 notes
Text
Healthcare Consulting - Delveinsight
Healthcare sector is leaping forward at a high pace. A better understanding of the indications and increased awareness in people have further acted as a driver in increased healthcare market size.
To meet the demands of the people and to provide value healthcare, pharma companies and healthcare institutions are trying their best to provide therapies and treatments that are effective and deliver quality results.
However, the whole process of the drug development, approval, and commercialization is a cumbersome and time-consuming process. The pharma companies, for the ease of the drug development and maximum yield of their product, hire healthcare consulting companies to give them insights into pharma and healthcare market trends.
With the fast pacing healthcare market trends, it is indispensable for the pharma companies to take guidance from a healthcare consultant for a clear view of the pharma market.
Healthcare Consulting Companies
Healthcare consulting companies are the advisory services providers that help pharmaceuticals and healthcare firms to take decisions that are fruitful in the long run and provide assistance that help them to outgrow in the market.
Healthcare consulting companies study the prevailing healthcare market scenario and present the forecasted trends for the market to help pharmaceuticals companies advance in the market.
DelveInsight, a leading healthcare consulting firm, provides healthcare advisory services to its clients for a better understanding of the healthcare market including trends on advanced diagnostic methods, health insurance services in different geographies, prevailing statistics comprising epidemiological models, therapies and treatments available, unmet needs, upcoming drugs, market drivers and barriers.
Moreover, healthcare consulting companies conduct a comprehensive study of the healthcare market to help its clients for plausible mergers and acquisitions, partners, licensing of their products, and drug pricing.
The healthcare consultants also provide a complete analysis of the competitors and their products that are in the market or are ought to be launched in the market. On the basis of that, Healthcare consulting firms guide its clients to prioritize its assets, which will be able to produce the maximum ROI upon commercialization.
Moreover, the consulting firms also provide an in-depth analysis of the pharma market segmented into different geographies and the information on guidelines of different regulatory bodies also help pharma companies to get a complete picture of the changing pharma market trends.
Healthcare Business Consulting Solutions:
1. Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
2. Healthcare Licensing Services: https://www.delveinsight.com/consulting/licensing-services
3. Healthcare Portfolio Management Services: https://www.delveinsight.com/consulting/pharmaceutical-portfolio-management-solutions
4. Healthcare Asset Prioritization Services: https://www.delveinsight.com/consulting/asset-prioritizaton-services
5. Healthcare R and D Analysis: https://www.delveinsight.com/consulting/r-and-d-analysis
6. Healthcare Merger and Acquisition: https://www.delveinsight.com/consulting/merger-and-acquisition
7. Healthcare Business Development Services: https://www.delveinsight.com/consulting/business-development-services
8. Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
9. Healthcare Pipeline Assessment: https://www.delveinsight.com/consulting/pipeline-assessment-services
10. Healthcare Market Assessment: https://www.delveinsight.com/consulting/market-assessment-services
11. Healthcare Regulatory Analysis: https://www.delveinsight.com/consulting/regulatory-analysis-services
12. Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
13. Healthcare Competitive Intelligence : https://www.delveinsight.com/consulting/competitive-intelligence-services
0 notes
Text
Pressure Ulcer Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Pressure Ulcers - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Pressure Ulcers - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pressure Ulcers, historical and forecasted epidemiology as well as the Pressure Ulcers market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts:
· As per the Agency for Healthcare Research & Quality (AHRQ), in the U.S., more than 2.5 million people get affected by pressure ulcers annually.
· As per World Health Organization, there were around 650 million including more than 1.9 billion adults of age 18 and above are obese in 2016.
· Pressure sores remain common, with a prevalence of 5 to 9% and more than 70% occurring in patients over 70 years of age.
Request for free sample report: https://www.delveinsight.com/sample-request/pressure-ulcers-market
View Report: https://www.delveinsight.com/report-store/pressure-ulcers-market
Scope of the Report
· The report covers the descriptive overview of Pressure Ulcers, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
· Comprehensive insight has been provided into the Pressure Ulcers epidemiology and treatment in the 7MM
· Additionally, an all-inclusive account of both the current and emerging therapies for Pressure Ulcers are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
· A detailed review of Pressure Ulcers market; historical and forecasted is included in the report, covering drug outreach in the 7MM
· The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pressure Ulcers market
Pressure ulcers, also known as pressure sores or bed sores, are localised damage to the skin and/or underlying tissue that usually occur over a bony prominence as a result of usually long-term pressure, or pressure in combination with shear or friction. The most common sites are the skin overlying the sacrum, coccyx, heels, and hips, though other sites can be affected, such as the elbows, knees, ankles, back of shoulders, or the back of the cranium.
Pressure ulcers occur due to pressure applied to soft tissue resulting in completely or partially obstructed blood flow to the soft tissue. Shear is also a cause, as it can pull on blood vessels that feed the skin. Pressure ulcers most commonly develop in individuals who are not moving about, such as those who are on chronic bedrest or consistently use a wheelchair. It is widely believed that other factors can influence the tolerance of skin for pressure and shear, thereby increasing the risk of pressure ulcer development. These factors are protein-calorie malnutrition, microclimate (skin wetness caused by sweating or incontinence), diseases that reduce blood flow to the skin, such as arteriosclerosis, or diseases that reduce the sensation in the skin, such as paralysis or neuropathy.
Request for free sample report: https://www.delveinsight.com/sample-request/pressure-ulcers-market
View Report: https://www.delveinsight.com/report-store/pressure-ulcers-market
Some of the companies covered:
Mölnlycke Health Care AB.
ConvaTec Group Plc
B. Braun Melsungen AG
Coloplast Corp
Smith & Nephew
3M
Integra LifeSciences Corporation.
Cardinal Health.
Tissue Regenix
Other prominent players
Request for free sample report: https://www.delveinsight.com/sample-request/pressure-ulcers-market
View Report: https://www.delveinsight.com/report-store/pressure-ulcers-market
Table of contents:
1. Key Insights
2. Executive Summary of Pressure Ulcers
3. Competitive Intelligence Analysis for Pressure Ulcers
4. Pressure Ulcers: Market Overview at a Glance
4.1. Pressure Ulcers Total Market Share (%) Distribution in 2017
4.2. Pressure Ulcers Total Market Share (%) Distribution in 2030
5. Pressure Ulcers: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Pressure Ulcers Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Pressure Ulcers Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Pressure Ulcers Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Pressure Ulcers Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Pressure Ulcers Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Pressure Ulcers Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Pressure Ulcers Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Pressure Ulcers Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Pressure Ulcers Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Pressure Ulcers Treatment and Management
8.2. Pressure Ulcers Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Pressure Ulcers Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Pressure Ulcers: Seven Major Market Analysis
13.1. Key Findings
13.2. Pressure Ulcers Market Size in 7MM
13.3. Pressure Ulcers Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Pressure Ulcers Total Market Size in the United States
15.1.2. Pressure Ulcers Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Pressure Ulcers Total Market Size in Germany
15.3.2. Pressure Ulcers Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Pressure Ulcers Total Market Size in France
15.4.2. Pressure Ulcers Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Pressure Ulcers Total Market Size in Italy
15.5.2. Pressure Ulcers Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Pressure Ulcers Total Market Size in Spain
15.6.2. Pressure Ulcers Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Pressure Ulcers Total Market Size in the United Kingdom
15.7.2. Pressure Ulcers Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Pressure Ulcers Total Market Size in Japan
15.8.3. Pressure Ulcers Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Pressure Ulcers
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for detailed TOC: https://www.delveinsight.com/sample-request/pressure-ulcers-market
Related Reports:
Pressure Ulcers - Pipeline Insights, 2020
"Pressure Ulcers Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pressure Ulcers market.
Pressure Ulcers - Epidemiology Forecast to 2030
DelveInsight's 'Pressure Ulcers - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Pressure Ulcers epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/
0 notes
Text
Kidney Transplant Rejection Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Kidney Transplant Rejection - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Kidney Transplant Rejection - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Kidney Transplant Rejection, historical and forecasted epidemiology as well as the Kidney Transplant Rejection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Companies:
· Alphamab Oncology
· Amgen Inc
· Amyndas Pharmaceuticals LLC
· Astellas Pharma Inc
· Bristol-Myers Squibb Co
· Enceladus Pharmaceuticals BV
· Genzyme Corp
· Hansa Biopharma AB
· Helocyte Biosciences Inc
· Hillhurst Biopharmaceuticals Inc
· Idogen AB
· ITB-Med AB
· JN Biosciences LLC
· Junten Bio Co Ltd
· Kiniksa Pharmaceuticals Ltd
· Kronos Bio Inc
· Kyowa Kirin Co Ltd
· Lyndra Therapeutics Inc.
· Mabtech Ltd
· Medeor Therapeutics Inc
· MyeloRx LLC
· Nekonal Sarl
· NextCell Pharma AB
· Novartis AG
· OSE Immunotherapeutics
· Paranta Biosciences Ltd
· Pharmapraxis
· Rigel Pharmaceuticals Inc
· Sangamo Therapeutics Inc
· Talaris Therapeutics Inc
· TolerogenixX GmbH
· TRACT Therapeutics Inc
· Veloxis Pharmaceuticals AS
· Viela Bio Inc
Request for free sample report: https://www.delveinsight.com/report-store/kidney-transplant-rejection-market
View Report: https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market
Scope of the Report
The report covers the descriptive overview of Kidney Transplant Rejection, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Kidney Transplant Rejection epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Kidney Transplant Rejection are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Kidney Transplant Rejection market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Kidney Transplant Rejection market
Request for free sample report: https://www.delveinsight.com/report-store/kidney-transplant-rejection-market
View Report: https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market
Key Questions
What was the Kidney Transplant Rejection market share (%) distribution in 2017 and how it would look like in 2030?
What would be the Kidney Transplant Rejection total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Kidney Transplant Rejection market size during the forecast period (2017-2030)?
At what CAGR, the Kidney Transplant Rejection market is expected to grow in 7MM during the forecast period (2017-2030)?
What would be the Kidney Transplant Rejection market outlook across the 7MM during the forecast period (2017-2030)?
What would be the Kidney Transplant Rejection market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
What is the disease risk, burden and unmet needs of the Kidney Transplant Rejection?
What is the historical Kidney Transplant Rejection patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Kidney Transplant Rejection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Kidney Transplant Rejection?
Out of all 7MM countries, which country would have the highest prevalent population of Kidney Transplant Rejection during the forecast period (2017-2030)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Request for free sample report: https://www.delveinsight.com/report-store/kidney-transplant-rejection-market
View Report: https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market
Table of Contents:
1. Key Insights
2. Executive Summary of Kidney Transplant Rejection
3. Competitive Intelligence Analysis for Kidney Transplant Rejection
4. Kidney Transplant Rejection: Market Overview at a Glance
4.1. Kidney Transplant Rejection Total Market Share (%) Distribution in 2017
4.2. Kidney Transplant Rejection Total Market Share (%) Distribution in 2030
5. Kidney Transplant Rejection: Disease Background and Overview
6. Patient Journey
7. Kidney Transplant Rejection Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Kidney Transplant Rejection Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
13. Kidney Transplant Rejection: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Kidney Transplant Rejection
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/
0 notes
Text
Top 10 Pharmaceutical Conferences 2021
The most thrilling international pharma events, from conferences to meetings & workshops, this is the list not to be missed for pharma professionals.
The most important gatherings for producers, suppliers, distributors, buyers and so on.. Grab your agenda and take a deep dive to schedule this year’s professional agenda. This list will be updated throughout the year!
Check out our list of Top 10 Pharmaceutical conferences:
1. International Conference on Cell and Gene Therapy
The International Research Conference is a federated organization dedicated to bringing together a significant number of diverse scholarly events for presentation within the conference program. Events will run over a span of time during the conference depending on the number and length of the presentations. With its high quality, it provides an exceptional value for students, academics and industry researchers.
Location: Paris, France
Dates: July 19-20, 2021
View Website: https://waset.org/cell-and-gene-therapy-conference
2. BIO-Europe Spring 2021
BIO-Europe® Spring is held annually in different cities and is an international forum to promote business development between pharmaceutical, financial and biotechnology companies. The event is Europe's largest partnering conference serving the global biotech industry. At this conference leading decision makers of the biotechnology, pharmaceutical and financial industry employed at emerging companies meet annually. Please note: Due to the effects of the corona virus, the fair will be held as an online event only.
Location: Barcelona
Dates: March 22–25, 2021
View Website : https://informaconnect.com/bioeurope-spring/?_ga=2.139511219.1009373759.1605085190-251309033.1605085190
��3. DUPHAT- 2021
DUPHAT exhibition spans the entire value chain of the industry from drugs manufacturing of medicine, OTC and retail products distribution within the pharmacy network. The growing population, the improvement of healthcare system together combined with the regional affluent lifestyle make the pharmaceutical segment a lucrative industry.
Location: DICEC, Dubai
Dates: 09 - 11 March 2021
View Website: https://duphat.ae/
4. CPHI India 2021
CPhI & P-MEC India’s networking features give you access to some of the country’s leading pharma figures who can share a wealth of knowledge and inside insights, while the event’s pre-connect congress and conference programme let you learn the latest trends, innovations, challenges and opportunities relating to India’s pharma market.
Location: India Expo Center, Greater Noida, Delhi NCR, India
Dates: 27-29 January 2021
View Website: https://www.cphi.com/india/en/lp-ppc/join-us-in-delhi.html?utm_source=AdWords&utm_medium=Paid%20Search&utm_campaign=HLN20PMI-VK-Visprom-PaidSearch&gclid=CjwKCAiAtK79BRAIEiwA4OskBtje5msH693kA0nLgzbQjARtsj7-1hnZ6fAwkjnEOOTdswZ4DZlalBoCz4cQAvD_BwE
5. DIA Europe 2021
DIA Europe 2021 programme includes the topics covered under 9 core thought leadership streams of DIA Europe 2021. These topics are designed to advance healthcare priorities and outcomes through innovation. Click below to view the Matrix and explore the topics.
Location: VIRTUAL
Dates: 15-19 MARCH 2021
View Website: https://www.diaglobal.org/en/flagship/dia-europe-2021/program/about-our-offerings
6. BIO Asia International Conference 2021
The BIO Asia International Conference in Tokyo brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments. Gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market and throughout the region.
Location: Grand Hyatt Tokyo, Japan
Dates: March 9-10, 2021
View Website: https://www.bio.org/events/bio-asia-international-conference
7. BIO International Convention
The Biotechnology Innovation Organization (BIO) announced today it will be moving the 2020 BIO International Convention scheduled for June 8-11 in San Diego to an online platform, in lieu of an in-person event for this year. The decision was based on the impact of COVID-19, the safety of the attendees and global health recommendations regarding large, in-person gatherings.
Location: New York, United States
Dates: June 14-17, 2021
View Website : https://www.bio.org/events/bio-international-convention
8. CAR TCR EUROPE 2021
The CAR-TCR Digital Summit Europe is the definitive platform for the European community to advance novel cell constructs, breach the solid tumor microenvironment, and deliver affordable CAR and TCR technologies to patients in need.Providing you with the most comprehensive program this side of the Atlantic, this summit brings you exclusive insights from the innovators breaking the glass ceiling in T cell engineering, manufacturing, safety management and patient accessibility.
Location: Digital Event
Dates: 16th–18th February 2021
View Website: https://cartcr-europe.com/
9. Pharma Forum 2021
We know nothing beats face-to-face interaction, but the health and safety of our Pharma Forum community takes priority. Pharma Forum 2021 will not only be different from years past, but will also incorporate the feedback received from our June virtual event, making March 22 - 24 virtual event experience even better than ever.
Location: Marriott Marquis, NYC.
Dates: March 22-24 & Sept 23-25, 2021
View Website: https://informaconnect.com/pharma-forum/
10. 4th Annual Bioprocessing Summit Europe
Bioprocessing Summit Europe brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for the development, manufacture and quality of antibodies, vaccines and gene therapies. This four track virtual conference, which is the fastest growing bioprocessing conference in Europe, presents detailed case studies and interactive discussions in cell culture, scale-up, continuous processing, recovery, purification, process and product characterization,
and formulation.
Location: Virtual
Dates: March 16-17, 2021
View Website: https://www.bioprocessingeurope.com/
0 notes
Text
Chronic Hepatitis B Virus Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Chronic Hepatitis B Virus - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Chronic Hepatitis B Virus - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Hepatitis B Virus , historical and forecasted epidemiology as well as the Chronic Hepatitis B Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Reports key facts-
1. In 2016, WHO set the target of eliminating chronic HBV as a public health threat by 2030. Elimination of HBV by 2030 will require diagnosis of 90% of people infected with HBV and antiviral treatment of 80% of diagnosed people eligible for therapy.
2. As per DelveInsight’s analysts, the t otal prevalent cases of CHB were 5,797,240 in 2017, which are expected to rise during the study period (2017-2030).
3. Among the 7MM, the United States accounted for nearly 39% of the total prevalent population of CHB in the year 2017.
4. Low diagnosis rate observed across the 7MM and possible factors could be people infected with CHB often have no symptoms and not aware about CHB and also there is overall lack of awareness surrounding HBV necessitates provider education on cut-off values for abnormal levels of alanine aminotransferase (ALT)
Request for Sample Page: https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market
View Report: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
Scope of Report:
· The report covers the descriptive overview of Chronic Hepatitis B Virus , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
· Comprehensive insight has been provided into the Chronic Hepatitis B Virus epidemiology and treatment in the 7MM
· Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Hepatitis B Virus are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
· A detailed review of Chronic Hepatitis B Virus market; historical and forecasted is included in the report, covering drug outreach in the 7MM
· The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Hepatitis B Virus market
Chronic Hepatitis B Virus is a life-threatening and one of the most common liver infections around the globe. It is caused by the hepatitis B virus (HBV), which attacks and injures the liver. HBV can cause both acute and chronic disease. If an individual suffers from HBV infection which lasts more than six months, then the infection becomes chronic. Having chronic hepatitis B (CHB) increases the risk of developing liver failure, liver cancer or cirrhosis. HBV is mostly transmitted through blood and infected bodily fluids. It can be passed to others through direct contact with blood, unprotected sex, use of illegal drugs, unsterilized or contaminated needles.
Request for Sample Page: https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market
View Report: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
Epidemiology
The Chronic Hepatitis B Virus epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Chronic Hepatitis B Virus epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Chronic Hepatitis B Virus epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Some of key companies
· GlaxoSmithKline
· Ionis Pharma
· Janssen Sciences
· Hoffmann-La Roche
· Gilead Sciences
· Assembly Biosciences
Name of drugs covered
· GSK3228836
· JNJ-56136379 And JNJ-3989 ± JNJ-6379 +NUC
· RG7907 + RG7854 + NUC
· Selgantolimod (GS-9688)
· Vebicorvir (ABI-H0731) +NUC
· And Many Others
View Report: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
Request for Sample Page: https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market
Table of content:
1. Key Insights
2. Executive Summary of Chronic Hepatitis B Virus
3. Competitive Intelligence Analysis for Chronic Hepatitis B Virus
4. Chronic Hepatitis B Virus : Market Overview at a Glance
5. Chronic Hepatitis B Virus : Disease Background and Overview
6. Patient Journey
7. Chronic Hepatitis B Virus Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Chronic Hepatitis B Virus Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Chronic Hepatitis B Virus: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Chronic Hepatitis B Virus
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Sample Page: https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-market
View Report: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website:https://www.delveinsight.com/
0 notes
Text
Palmar Hyperhidrosis Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Palmar Hyperhidrosis - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Palmar Hyperhidrosis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Palmar Hyperhidrosis, historical and forecasted epidemiology as well as the Palmar Hyperhidrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Facts:
• According to the survey, titled “Epidemiological study and considerations of primary focal hyperhidrosis in Japan: From questionnaire analysis” by Fujimoto et al., primary focal hyperhidrosis involving in certain sites, is higher in male than females.
• As per another survey titled “US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey” by Strutton et al., approximately 3% of the US population suffer from hyperhidrosis.
• According to a study titled “Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis” by Gossot et al., in a series of 382 French patients treated with endoscopic thoracic sympathectomy (ETS), more than a quarter had palmar and plantar hyperhidrosis, >50% had palmoplantar and axillary hyperhidrosis, less than 10% had palmoplantar and facial hyperhidrosis, 5% had all areas involved, and 8% had axillary hyperhidrosis only.
• As per the article by Hajjar et al., titled, “The Quality of Life and Satisfaction Rate of Patients With Upper Limb Hyperhidrosis Before and After Bilateral Endoscopic Thoracic Sympathectomy”, hyperhidrosis is a functional disorder identified by excessive sweating and its incidence is approximately 1% in any population.
Scope of the Report
The report covers the descriptive overview of Palmar Hyperhidrosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Palmar Hyperhidrosis epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Palmar Hyperhidrosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Palmar Hyperhidrosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Palmar Hyperhidrosis market
View Report: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
Request for free sample report: https://www.delveinsight.com/sample-request/palmar-hyperhidrosis-market
Palmar hyperhidrosis, or excessive hand sweating, is a common condition affecting 1-3% of the population. It usually starts in childhood or adolescence. Sweaty hands can significantly affect a person socially and emotionally.
Many factors can contribute to the condition, including genetic influences as well as physical and emotional stress. A family history is present in up to 30% of cases. Palmar hyperhidrosis affects both hands equally and can range from mild clammy hands to severe sweating. It stops when sleep.
Palmar hyperhidrosis Diagnosis
The diagnosis is usually made based on a history of excessive sweating. No investigations are needed.
Palmar hyperhidrosis Treatment
Treatment will depend on how severe the sweating is and which previous treatments have been successful. Topical treatments
· Topical treatments: Some mild to moderate cases can respond to topical treatments such as aluminium chloride hexahydrate (Driclor).
· Iontophoresis may be considered for cases which do not respond to topical treatments.
· Botox injections can treat sweaty hands safely and effectively. However, the treatment is not subsidised under Medicare-PBS and the cost limits its wider use.
· Anticholinergic tablets (such as oxybutynin and propantheline bromide) can be useful in treating palmar hyperhidrosis. However, side effects such as constipation, dry mouth and drowsiness are common.
· Endoscopic thoracic sympathectomy (ETS) is a surgical treatment option for various forms of hyperhidrosis
View Report: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
Request for free sample report: https://www.delveinsight.com/sample-request/palmar-hyperhidrosis-market
Some of the Companies:
· Dermira
· Atacama Therapeutics
· Stiefel, a GSK Company
· Brickell Biotech
· Allergan
· And Many Others
Drugs Covered:
• Glycopyrronium
• Dexmecamylamine
• Umeclidinium
• BBI-4000
• BTX-A
• And Many Other
Request for free sample report: https://www.delveinsight.com/sample-request/palmar-hyperhidrosis-market
View Report: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
Table of Contents:
1. Key Insights
2. Executive Summary of Palmar Hyperhidrosis
3. Competitive Intelligence Analysis for Palmar Hyperhidrosis
4. Palmar Hyperhidrosis: Market Overview at a Glance
4.1. Palmar Hyperhidrosis Total Market Share (%) Distribution in 2017
4.2. Palmar Hyperhidrosis Total Market Share (%) Distribution in 2030
5. Palmar Hyperhidrosis: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Palmar Hyperhidrosis Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Palmar Hyperhidrosis Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Palmar Hyperhidrosis Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Palmar Hyperhidrosis Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Palmar Hyperhidrosis Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Palmar Hyperhidrosis Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Palmar Hyperhidrosis Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Palmar Hyperhidrosis Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Palmar Hyperhidrosis Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Palmar Hyperhidrosis Treatment and Management
8.2. Palmar Hyperhidrosis Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Palmar Hyperhidrosis Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Palmar Hyperhidrosis: Seven Major Market Analysis
13.1. Key Findings
13.2. Palmar Hyperhidrosis Market Size in 7MM
13.3. Palmar Hyperhidrosis Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Palmar Hyperhidrosis Total Market Size in the United States
15.1.2. Palmar Hyperhidrosis Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Palmar Hyperhidrosis Total Market Size in Germany
15.3.2. Palmar Hyperhidrosis Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Palmar Hyperhidrosis Total Market Size in France
15.4.2. Palmar Hyperhidrosis Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Palmar Hyperhidrosis Total Market Size in Italy
15.5.2. Palmar Hyperhidrosis Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Palmar Hyperhidrosis Total Market Size in Spain
15.6.2. Palmar Hyperhidrosis Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Palmar Hyperhidrosis Total Market Size in the United Kingdom
15.7.2. Palmar Hyperhidrosis Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Palmar Hyperhidrosis Total Market Size in Japan
15.8.3. Palmar Hyperhidrosis Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Palmar Hyperhidrosis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for
Browse through our vast repository from here.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/
0 notes
Text
Bradykinesia Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Bradykinesia - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Bradykinesia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Bradykinesia, historical and forecasted epidemiology as well as the Bradykinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts:
· Up to 98% of all people with Parkinson’s experience slowness of movement.
· The most common cause of Bradykinesia is Parkinson's disease, and conditions related to Parkinson's disease.
· More men than women typically develop Bradykinesia
View Report: https://www.delveinsight.com/report-store/bradykinesia-market
Request for free sample report: https://www.delveinsight.com/sample-request/bradykinesia-market
Scope of the Report
• The report covers the descriptive overview of Bradykinesia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Bradykinesia epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Bradykinesia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Bradykinesia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Bradykinesia market
View Report: https://www.delveinsight.com/report-store/bradykinesia-market
Request for free sample report: https://www.delveinsight.com/sample-request/bradykinesia-market
Bradykinesia refers to slowness of movement, and is a common symptom in dopamine-deficient diseases such as AADC deficiency and Parkinson’s disease. Bradykinesia is caused by an imbalance in levels of the neurotransmitter dopamine that is required for proper communication between brain and muscle cells.
Bradykinesia is an early sign of AADC deficiency, but is not constantly observed. Periods of normal movement usually alternate with periods of slow movement that affect a patient’s quality of life.
Other indications of bradykinesia include micrographia (small or cramped handwriting), hesitation in movement, and noticeably less blinking. Bradykinesia may also develop into hypokinesia (reduced movement) or akinesia (complete loss of movement).
Key Questions
What was the Bradykinesia market share (%) distribution in 2017 and how it would look like in 2030?
What would be the Bradykinesia total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Bradykinesia market size during the forecast period (2017-2030)?
At what CAGR, the Bradykinesia market is expected to grow in 7MM during the forecast period (2017-2030)?
What would be the Bradykinesia market outlook across the 7MM during the forecast period (2017-2030)?
What would be the Bradykinesia market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
What is the disease risk, burden and unmet needs of the Bradykinesia?
What is the historical Bradykinesia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Bradykinesia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Bradykinesia?
Out of all 7MM countries, which country would have the highest prevalent population of Bradykinesia during the forecast period (2017-2030)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
View Report: https://www.delveinsight.com/report-store/bradykinesia-market
Request for free sample report: https://www.delveinsight.com/sample-request/bradykinesia-market
Table of Contents:
1. Key Insights
2. Executive Summary of Bradykinesia
3. Competitive Intelligence Analysis for Bradykinesia
4. Bradykinesia: Market Overview at a Glance
4.1. Bradykinesia Total Market Share (%) Distribution in 2017
4.2. Bradykinesia Total Market Share (%) Distribution in 2030
5. Bradykinesia: Disease Background and Overview
6. Patient Journey
7. Bradykinesia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Bradykinesia Treatment and Management
8.2. Bradykinesia Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Bradykinesia Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Bradykinesia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Bradykinesia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
View Report: https://www.delveinsight.com/report-store/bradykinesia-market
Request for Detailed TOC: https://www.delveinsight.com/sample-request/bradykinesia-market
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for
Browse through our vast repository from here.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/
0 notes
Text
Facioscapulohumeral Muscular Dystrophy Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Facioscapulohumeral Muscular Dystrophy - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Facioscapulohumeral Muscular Dystrophy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Facioscapulohumeral Muscular Dystrophy, historical and forecasted epidemiology as well as the Facioscapulohumeral Muscular Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts:
· As per the “National Organization of Rare Disorders”, FSHD appears to affect males and females in relatively equal numbers. The estimated prevalence is between four and ten per 100,000 people.
· According to Statland et al. (2016), “Since 1991, studies have shown the worldwide prevalence of FSHD ranging between 2.03 and 6.8 per 100,000 individuals, and the prevalence of FSHD in the United States is commonly quoted as 1 in 15,000 or approximately 21,000 individuals”.
· According to “FSHD society” 2019, FSHD is the most prevalent of the nine primary types of muscular dystrophy affecting adults and children. It is estimated to affect about 870,000 individuals worldwide, the actual number of individuals with FSHD could be significantly high due to undiagnosed cases.
· According to “FSHD society” 2019 approximately 95% of FSHD cases are known as Type 1 or FSHD1, which is linked to deletions of D4Z4 units on chromosome 4. The remaining five percent of FSHD cases have normal-length D4Z4 regions on chromosome 4 and are called Type 2 or FSHD2.
· As per the “Muscular Dystrophy UK” 2019, it is estimated that around 2000–2500 people are affected with FSHD in the United Kingdom.
View Report: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market
Request free Sample Report: https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market
Scope of the Report:
· The report covers the descriptive overview of Facioscapulohumeral Muscular Dystrophy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
· Comprehensive insight has been provided into the Facioscapulohumeral Muscular Dystrophy epidemiology and treatment in the 7MM
· Additionally, an all-inclusive account of both the current and emerging therapies for Facioscapulohumeral Muscular Dystrophy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
· A detailed review of Facioscapulohumeral Muscular Dystrophy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
· The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Facioscapulohumeral Muscular Dystrophy market
Request free Sample Report: https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market
View Report: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market
Facioscapulohumeral muscular dystrophy (FSHD) is a disorder characterized by muscle weakness and wasting (atrophy). The disorder gets its name from muscles that are affected in the face (facio), around the shoulder blades (scapulo), and in the upper arms (humeral). Hamstring and trunk muscles are affected -early on but are less well recognized. Other arm and leg muscles are frequently eventually affected in the course of the disease. Symptoms usually appear before age 20, but can begin in infancy or later in adulthood. Severity of the condition varies widely and some people with the disease allele remain asymptomatic. FSHD is most typically characterized by relatively slow disease progression. Specific symptoms and findings may also vary in range and severity, including among affected members of the same family. Life expectancy is not shortened. FSHD is usually inherited as an autosomal dominant genetic condition.
Some of the Companies:
· Fulcrum Therapeutics
· aTyr Pharma
· Acceleron Pharma
· And Many Others
Drugs Covered:
· Losmapimod
· ATYR1940
· ACE-083
· And Many Others
View Report: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market
Request free Sample Report: https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market
Table of Contents:
1. Key Insights
2. Executive Summary of Facioscapulohumeral Muscular Dystrophy
3. Competitive Intelligence Analysis for Facioscapulohumeral Muscular Dystrophy
4. Facioscapulohumeral Muscular Dystrophy: Market Overview at a Glance
4.1. Facioscapulohumeral Muscular Dystrophy Total Market Share (%) Distribution in 2017
4.2. Facioscapulohumeral Muscular Dystrophy Total Market Share (%) Distribution in 2030
5. Facioscapulohumeral Muscular Dystrophy: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Facioscapulohumeral Muscular Dystrophy Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Facioscapulohumeral Muscular Dystrophy Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Facioscapulohumeral Muscular Dystrophy Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Facioscapulohumeral Muscular Dystrophy Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Facioscapulohumeral Muscular Dystrophy Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Facioscapulohumeral Muscular Dystrophy Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Facioscapulohumeral Muscular Dystrophy Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Facioscapulohumeral Muscular Dystrophy Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Facioscapulohumeral Muscular Dystrophy Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Facioscapulohumeral Muscular Dystrophy Treatment and Management
8.2. Facioscapulohumeral Muscular Dystrophy Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Facioscapulohumeral Muscular Dystrophy Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Facioscapulohumeral Muscular Dystrophy: Seven Major Market Analysis
13.1. Key Findings
13.2. Facioscapulohumeral Muscular Dystrophy Market Size in 7MM
13.3. Facioscapulohumeral Muscular Dystrophy Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Facioscapulohumeral Muscular Dystrophy Total Market Size in the United States
15.1.2. Facioscapulohumeral Muscular Dystrophy Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Facioscapulohumeral Muscular Dystrophy Total Market Size in Germany
15.3.2. Facioscapulohumeral Muscular Dystrophy Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Facioscapulohumeral Muscular Dystrophy Total Market Size in France
15.4.2. Facioscapulohumeral Muscular Dystrophy Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Facioscapulohumeral Muscular Dystrophy Total Market Size in Italy
15.5.2. Facioscapulohumeral Muscular Dystrophy Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Facioscapulohumeral Muscular Dystrophy Total Market Size in Spain
15.6.2. Facioscapulohumeral Muscular Dystrophy Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Facioscapulohumeral Muscular Dystrophy Total Market Size in the United Kingdom
15.7.2. Facioscapulohumeral Muscular Dystrophy Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Facioscapulohumeral Muscular Dystrophy Total Market Size in Japan
15.8.3. Facioscapulohumeral Muscular Dystrophy Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Facioscapulohumeral Muscular Dystrophy
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
View Report: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market
Request free Sample Report: https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website:https://www.delveinsight.com/
0 notes
Text
Epidermolysis Bullosa Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on ‘Epidermolysis Bullosa (EB)-Market Insights, Epidemiology, and Market Forecast–2030’.
DelveInsight’s ‘Epidermolysis Bullosa (EB)-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the EB, historical and forecasted epidemiology as well as the EB market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Epidermolysis Bullosa Key Findings
According to the publisher's, the total prevalent population of EB in seven major markets ranges was 41,509 in 2017.
The total diagnosed prevalent cases of EB in the 7MM was 39,433 in 2017.
In 2017, there were 26,104 prevalent cases of EB in the United States. In the same years, there were a total of 24,799 diagnosed prevalent cases of EB in the United States.
Epidermolysis Bullosa is of several types, and three major types of Epidermolysis bullosa includes Epidermolysis bullosa simplex (EBS), junctional EB (JEB), and dystrophic EB (DEB). Assessments as perthe publisher's analysts show that the majority of cases of EB are EBS in the United States. In 2017, there were 14,879 cases of EBS, 1,240 cases of JEB, and 8,680 cases of DEB in the United States. DEB is further divided as recessive and dominant.
Out of 8,680 cases of DEB in the United States in 2017, 4,554 cases were dominant DEB and 4,126 cases were recessive DEB.
Among the European countries, the United Kingdom had the highest prevalent population of EB with 5,037 cases, followed by Germany which had a prevalent population of 4,919 in 2017. On the other hand, Spain had the lowest prevalent population of 928 in 2017.
View Report: https://www.delveinsight.com/report-store/epidermolysis-bullosa-market
Request for free sample report: https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
Epidermolysis Bullosa (EB) Emerging Drugs
Oleogel-S10 (AP-101): Amryt Pharma
Oleogel-S10 (AP-101) is a topical product that is being developed for the treatment of EB. It incorporates a betulin-based active ingredient formulated with sunflower oil. AP-101 acts by promoting the differentiation and migration of keratinocytes (skin cells with wound repair capabilities) as well as transiently increasing the level of proinflammatory mediators (which also promote healing).
AP101 has already received marketing approval for the treatment of partial-thickness wounds (PTWs) in adults from the European Commission in January 2016 under the brand name Episalvan. The company is also developing AP103, a potential treatment for patients with RDEB. Oleogel-S10 is currently in phase III clinical trial and recently reported positive unblinded interim efficacy and safety analyses.
EB-101: Abeona Therapeutics
EB-101 (LZRSE-Col7A1) is an autologous, ex-vivo gene therapy in which the COL7A1 gene is inserted into a patient's skin cells (keratinocytes) for the treatment of the underlying disease in recessive dystrophic epidermolysis bullosa (RDEB). The patient's cell is genetically engineered in the lab to express a missing protein called type VII collagen and then these corrected cells will be transplanted back to the patient. These cells should then make type VII collagen. The process of adding inserting the correct type VII collagen gene into cells is called gene transfer. Post this process i.e. gene transfer the engineered cells are grown in culture into a sheet of cells that look like a plastic film. This sheet is then grafted to wounds.
The company has evaluated the safety of EB-101 in phase I/II trial in which product has shown significant results, wound treated with EB-101 were significantly healed >50% for more than two years post-administration.
CCP-020 (Diacerein 1% Ointment): Castle Creek Pharmaceuticals
CCP-020 (Diacerein 1% Ointment) is a topical ointment that is being developed by Castle Creek Pharmaceuticals for the treatment of EBS. The drug is engineered to potentially block the activity of interleukin-1? (IL-1?), a pro-inflammatory cytokine that is involved in the inflammatory signaling pathway associated with EBS. Blocking of IL-1? reduces the auto-inflammatory effects in the skin of patients with EBS and strengthen epidermal tissue and support healing.
Diacerein is a commercially available medicine used to treat osteoarthritis. Its therapeutic potential in treating blistering in patients with epidermolysis bullosa simplex was initially discovered by a team of researchers at the EB House Austria, University Clinic for Dermatology at the Paracelsus Medical University (PMU). Diacerein is commonly marketed as tablets but for EBS researchers have developed an ointment with 1% of diacerein. Presently Castle Creek is developing CCP-020 is in the phase II stage of development. Earlier a phase II trial of CCP-020 for EBS got terminated because an independent data monitoring committee suggested that the study will not meet statistical objectives.
View Report: https://www.delveinsight.com/report-store/epidermolysis-bullosa-market
Request for free sample report: https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
Companies Mentioned
Amryt Pharma
Abeona Therapeutics
Castle Creek Pharmaceuticals
RegeneRx
Krystal Biotech
Fibrocell Technologies/Castle Creek Pharmaceuticals
RHEACELL GmbH
Holostem Terapie Avanzate
StemRim/Shionogi
Phoenix Tissue Repair (BridgeBio Pharma, Inc)
Menlo Therapeutics
JCR Pharmaceuticals
Amicus Therapeutics
View Report: https://www.delveinsight.com/report-store/epidermolysis-bullosa-market
Request for free sample report: https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
Key Topics Covered:
1. Key Insights
2. Executive Summary of Epidermolysis Bullosa (EB)
3. Epidermolysis Bullosa (EB) Market Overview at a Glance
3.1. Market Share (%) Distribution of Epidermolysis Bullosa (EB) in 2017
3.2. Market Share (%) Distribution of Epidermolysis Bullosa (EB) in 2030
4. Epidermolysis Bullosa (EB): Disease Background and Overview
4.1. Introduction
4.2. Causes of Epidermolysis Bullosa
4.3. Signs and Symptoms of Epidermolysis Bullosa
4.4. Classification of Epidermolysis Bullosa
4.5. Pathophysiology of Epidermolysis Bullosa
4.6. Genetic Bases of Epidermolysis Bullosa
4.7. Diagnosis of Epidermolysis Bullosa
4.7.1. Diagnostic Guidelines
5. Case Reports
5.1. Dystrophic Epidermolysis Bullosa in Pregnancy: A Case Report of the Autosomal Dominant Subtype and Review of the Literature
5.2. Managing pain in children with epidermolysis bullosa
5.3. Epidermolysis bullosa: a case report
5.4. Newborn Infant with Epidermolysis Bullosa and Ankyloglossia
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
6.3. 7MM Total Prevalent Patient Population of Epidermolysis Bullosa
6.4. 7MM Diagnosed Prevalent Patient Population of Epidermolysis Bullosa
6.5. 7MM Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa
7. Country Wise-Epidemiology of Epidermolysis Bullosa
7.1. United States Epidemiology
7.1.1. Assumptions and Rationale
7.1.2. Total Prevalent Cases of Epidermolysis Bullosa in the United States
7.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United States
7.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States
7.2. EU5 Epidemiology
7.3. Japan Epidemiology
8. Treatment and Management of Epidermolysis Bullosa (EB)
8.1. Skin and Wound Management
8.2. General Management Principles
8.3. Special Considerations
8.4. Management of Chronic wounds in EB
8.5. Pain care for patients with epidermolysis bullosa: best care practice guidelines
9. Unmet Needs
10. Emerging Drugs
10.1. Key Cross Competition
10.2. Oleogel-S10 (AP-101): Amryt Pharma
10.2.1. Product Description
10.2.2. Other Development Activities
10.2.3. Clinical Development
10.2.4. Clinical Trials Information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. EB-101: Abeona Therapeutics
10.4. CCP-020 (Diacerein 1% Ointment): Castle Creek Pharmaceuticals
10.5. RGN-137: RegeneRx
10.6. B-VEC (KB103, Beremagene Geperpavec): Krystal Biotech
10.7. FCX-007: Fibrocell Technologies/Castle Creek Pharmaceuticals
10.8. Allo-APZ2-EB: RHEACELL GmbH
10.9. COL7 and LAMB3 gene therapy: Holostem Terapie Avanzate
10.10. KOI2 (Redasemtide/HMGB1 Peptides): StemRim/Shionogi
10.11. PTR-01 (BBP-589): Phoenix Tissue Repair (BridgeBio Pharma, Inc)
10.12. Serlopitant (VPD-737): Menlo Therapeutics
11. Failed Therapies for Epidermolysis Bullosa (EB)
11.1. JR-031: JCR Pharmaceuticals
11.1.1. Product Description
11.1.2. Other Development Activities
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Product Profile
11.2. Allantoin (Zorblisa): Amicus Therapeutics
12. Epidermolysis Bullosa: Seven Major Market Analysis
12.1. Key Findings
12.2. Market Methodology
12.3. Attribute Analysis
12.4. Market Size of Epidermolysis Bullosa in the 7MM
12.5. Market Size of Epidermolysis Bullosa by Therapies in the 7MM
13. Market Outlook: The United States
13.1. United States Market Size
13.1.1. The Total Market Size of Epidermolysis Bullosa
13.1.2. Market Size of Epidermolysis Bullosa by Therapies in the United States
14. Market Outlook: Europe
15. Market Outlook: Japan
16. Market Drivers
17. Market Barriers
18. SWOT Analysis
19. Reimbursement and Market Access
20. Recognized Establishments
21. Appendix
View Report: https://www.delveinsight.com/report-store/epidermolysis-bullosa-market
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website:https://www.delveinsight.com/
0 notes
Text
Primary Biliary Cirrhosis Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Primary Biliary Cirrhosis - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Primary Biliary Cirrhosis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Primary Biliary Cirrhosis, historical and forecasted epidemiology as well as the Primary Biliary Cirrhosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Companies:
According to American Association for the Study of Liver Diseases (AASLD), in 2016, the prevalence of PBC in the U.S. was estimated to vary from 1.91 to 40.2 per 100,000 persons
In UK, the prevalence of PBC is estimated to be 12.9 per 100,000 population, of which 90% of cases where reported in women
Epidemiological studies also revealed the prevalence of PBC to be around 27–54 per million cases in Japan
As per one study conducted by Daniel S. Smyk (February 2012), approximately 7–11% of PBC patients are males.
View Report: https://www.delveinsight.com/report-store/primary-biliary-cirrhosis-market
Request for free report: https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-market
Scope of the Report
The report covers the descriptive overview of Primary Biliary Cirrhosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Primary Biliary Cirrhosis epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Primary Biliary Cirrhosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Primary Biliary Cirrhosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Primary Biliary Cirrhosis market
Primary Biliary Cirrhosis (PBC) is a chronic, progressive liver disorder that mostly affects women and usually appears during middle age. It leads to inflammation and scarring of the small bile ducts. If PBC is untreated, it can lead to cirrhosis, or scarring of the entire liver, which can lead to liver failure.
PBC is divided into four stages with stage 1 being early disease, where this is no significant scarring, to stage 4, which is defined by cirrhosis.
The most common symptom of PBC is fatigue. When PBC is very severe, it can lead to yellow discoloration of the skin (jaundice).
PBC is common among women of middle age worldwide. The disease ratio among female to male is 9:1.
View Report: https://www.delveinsight.com/report-store/primary-biliary-cirrhosis-market
Request for free report: https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-market
Some of the Companies:
· Axcan Pharma
· Intercept Pharmaceuticals
· Calliditas Therapeutics
· CymaBay Therapeutics
· Fast Forward Pharmaceuticals
· Genkyotex
· And Many Others
Drugs Covered:
· Ursodeoxycholic acid
· Obeticholic acid
· NEFECON
· Seladelpar
· FFP104
· GKT831
· And Many Others
View Report: https://www.delveinsight.com/report-store/primary-biliary-cirrhosis-market
Request for free report: https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-market
Table of Contents:
1. Key Insights
2. Executive Summary of Primary Biliary Cirrhosis
3. Competitive Intelligence Analysis for Primary Biliary Cirrhosis
4. Primary Biliary Cirrhosis: Market Overview at a Glance
4.1. Primary Biliary Cirrhosis Total Market Share (%) Distribution in 2017
4.2. Primary Biliary Cirrhosis Total Market Share (%) Distribution in 2030
5. Primary Biliary Cirrhosis: Disease Background and Overview
6. Patient Journey
7. Primary Biliary Cirrhosis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Primary Biliary Cirrhosis Treatment and Management
8.2. Primary Biliary Cirrhosis Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Primary Biliary Cirrhosis Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Primary Biliary Cirrhosis: Seven Major Market Analysis
13.1. Key Findings
13.2. Primary Biliary Cirrhosis Market Size in 7MM
13.3. Primary Biliary Cirrhosis Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Primary Biliary Cirrhosis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
View Report: https://www.delveinsight.com/report-store/primary-biliary-cirrhosis-market
Request for free report: https://www.delveinsight.com/sample-request/primary-biliary-cirrhosis-market
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for
Browse through our vast repository from here.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/
0 notes
Text
Pruritus Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Pruritus - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Pruritus - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pruritus, historical and forecasted epidemiology as well as the Pruritus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Facts:
· A 2013 study by Shive et al. reported 77 million visits for itch in America over an 11-year period, with an average of 7 million visits per year, accounting for roughly 1 % of all physician visits.
· According to the study published by Nicholas et al., the prevalence of pruritus in the general population varies from 8 to 38 % worldwide.
· The study published by Laurent et al., suggested that in the database maintained by the Münster Competence Centre of Chronic Pruritus, 8% of cases of chronic itch could be associated with a neuropathic origin.
· As per the study by Emilie et al., the prevalence of patients experiencing pruritus following a burn injury has been noted to be as high as 93%. 70–83% of patients continue to be affected by pruritus 1 year after their burn injury, and 67–73% are affected 2 years post-burn injury.
Scope of the Report
The report covers the descriptive overview of Pruritus, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Pruritus epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Pruritus are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Pruritus market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pruritus market
View Report: https://www.delveinsight.com/report-store/pruritus-market
Request for free sample report: https://www.delveinsight.com/report-store/pruritus-market
Pruritus, or itching, although considered a benign symptom, is a frequent complaint heard by dermatologists and primary care physicians. It can have adverse effects on a patient’s wellbeing and can be incapacitating when severe.
The mechanisms of pruritus are not particularly well understood and are compounded by the subjective nature of the process itself. The condition occurs with a host of dermatological conditions, but can also be a marker of systemic disease.
Physiologically, itching is the conscious expression of cutaneous sensations that evoke the well-known scratch reflex. The purpose of this reflex is the removal of the noxious stimulus. Unfortunately, scratching can cause further damage to the skin and can perpetuate the problem. Severe pruritus can be relieved by self-trauma, essentially replacing itching with pain, but such action can result in chronic skin changes, such as lichenification, erythema, excoriation, and even lacerations.
Pruritus may be acute or chronic, localized or generalized. Chronic pruritus of unknown origin is defined as pruritus lasting six weeks or longer with no identified underlying cause. Chronic itch is defined as itch lasting more than 6 weeks and represents a veritable quagmire for clinicians, as it causes significant emotional distress in patients with negative effects on quality of life and sleep and is often difficult to treat.
View Report: https://www.delveinsight.com/report-store/pruritus-market
Request for free sample report: https://www.delveinsight.com/report-store/pruritus-market
Some of the Companies:
· Menlo Therapeutics
· Cara Therapeutics
· Trevi Therapeutics
· And Many Others
Drugs Covered:
· Serlopitant
· CR845
· Nalbuphine ER
· And Many Others
View Report: https://www.delveinsight.com/report-store/pruritus-market
Request for free sample report: https://www.delveinsight.com/report-store/pruritus-market
Table of Contents:
1. Key Insights
2. Executive Summary of Pruritus
3. Competitive Intelligence Analysis for Pruritus
4. Pruritus: Market Overview at a Glance
4.1. Pruritus Total Market Share (%) Distribution in 2017
4.2. Pruritus Total Market Share (%) Distribution in 2030
5. Pruritus: Disease Background and Overview
6. Patient Journey
7. Pruritus Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Pruritus Treatment and Management
8.2. Pruritus Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Pruritus Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Pruritus: Seven Major Market Analysis
13.1. Key Findings
13.2. Pruritus Market Size in 7MM
13.3. Pruritus Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Pruritus
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
View Report: https://www.delveinsight.com/report-store/pruritus-market
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for
Browse through our vast repository from here.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/
0 notes
Text
Optic Neuritis Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Optic Neuritis - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Optic Neuritis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Optic Neuritis, historical and forecasted epidemiology as well as the Optic Neuritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts:
· A rare condition with an estimated annual incidence of 6.4 per 100,000 cases in population in the United States.
· ON is most common among adults, age 20 to 40 years, and its symptoms generally improve in 80 percent of patients over few weeks.
· More females are affected than males and approximately five out of every one-hundred thousand people are affected by ON every year
View Report: https://www.delveinsight.com/report-store/optic-neuritis-market
Request for free sample report: https://www.delveinsight.com/sample-request/optic-neuritis-market
Scope of the Report
The report covers the descriptive overview of Optic Neuritis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Optic Neuritis epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Optic Neuritis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Optic Neuritis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Optic Neuritis market
Optic Neuritis (ON) is the swelling of the eye’s optic nerve. The optic nerve carries light signals from the back of the eye to the brain so that a person can see. A person cannot see clearly if the optic nerve is swollen, damaged or is infected.
It is an acute rare disorder which usually occurs in one eye, and is being characterized by the symptoms including blurring of vision, a loss of part or all of central vision, reduced color vision, and dimness of vision.
Most patients with ON have eye pain which characteristically worsen with movement of the eye.
View Report: https://www.delveinsight.com/report-store/optic-neuritis-market
Request for free sample report: https://www.delveinsight.com/sample-request/optic-neuritis-market
Some of the companies covered:
· Biogen
· Mitochon Pharmaceuticals
· Noveome Biotherapeutics
· And Many Others
Drugs Covered:
· Opicinumab
· MP101
· ST266
· And Many Others
View Report: https://www.delveinsight.com/report-store/optic-neuritis-market
Request for free sample report: https://www.delveinsight.com/sample-request/optic-neuritis-market
Table of Contents:
1. Key Insights
2. Executive Summary of Optic Neuritis
3. Competitive Intelligence Analysis for Optic Neuritis
4. Optic Neuritis: Market Overview at a Glance
4.1. Optic Neuritis Total Market Share (%) Distribution in 2017
4.2. Optic Neuritis Total Market Share (%) Distribution in 2030
5. Optic Neuritis: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Optic Neuritis Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Optic Neuritis Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Optic Neuritis Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Optic Neuritis Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Optic Neuritis Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Optic Neuritis Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Optic Neuritis Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Optic Neuritis Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Optic Neuritis Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Optic Neuritis Treatment and Management
8.2. Optic Neuritis Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Optic Neuritis Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Optic Neuritis: Seven Major Market Analysis
13.1. Key Findings
13.2. Optic Neuritis Market Size in 7MM
13.3. Optic Neuritis Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Optic Neuritis Total Market Size in the United States
15.1.2. Optic Neuritis Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Optic Neuritis Total Market Size in Germany
15.3.2. Optic Neuritis Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Optic Neuritis Total Market Size in France
15.4.2. Optic Neuritis Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Optic Neuritis Total Market Size in Italy
15.5.2. Optic Neuritis Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Optic Neuritis Total Market Size in Spain
15.6.2. Optic Neuritis Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Optic Neuritis Total Market Size in the United Kingdom
15.7.2. Optic Neuritis Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Optic Neuritis Total Market Size in Japan
15.8.3. Optic Neuritis Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Optic Neuritis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
View Report: https://www.delveinsight.com/report-store/optic-neuritis-market
Request for free sample report: https://www.delveinsight.com/sample-request/optic-neuritis-market
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for
Browse through our vast repository from here.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/
0 notes
Text
Primary Progressive Multiple Sclerosis (PPMS) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Primary Progressive Multiple Sclerosis (PPMS) - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Primary Progressive Multiple Sclerosis (PPMS) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Primary Progressive Multiple Sclerosis (PPMS), historical and forecasted epidemiology as well as the Primary Progressive Multiple Sclerosis (PPMS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts:
· As per the National Multiple Sclerosis Society, about 15% of the total estimated MS patients in the United States with multiple sclerosis (MS) have the primary progressive form of the disease (PPMS).
· According to a study by Costa-Arpín et al. (2020), in a Spanish cohort, 71.17% had relapsing-remitting MS, 16.55% secondary progressive MS, 7.59% primary progressive MS, and 0.69% progressive relapsing MS.
· As per the estimates provided by Columbia University Medical Center (2018), on average, people with the primary progressive form of MS start having symptoms between ages 35 and 39.
· According to a review article titled “Primary Progressive Multiple Sclerosis” published by Giovannon et al. (2012), the female to male ratio is generally 1:1 with regard to PPMS and 2 or even 3:1 for relapse onset disease. As seen by changes in the sex ratio, the increasing female preponderance of MS seems to be driven by relapse-onset disease, with the incidence of PPMS remaining relatively constant.
View Report: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market
Request for free sample report: https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-market
Scope of the Report
The report covers the descriptive overview of Primary Progressive Multiple Sclerosis (PPMS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Primary Progressive Multiple Sclerosis (PPMS) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Primary Progressive Multiple Sclerosis (PPMS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Primary Progressive Multiple Sclerosis (PPMS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Primary Progressive Multiple Sclerosis (PPMS) market
View Report: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market
Request for free sample report: https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-market
Primary-Progressive Multiple Sclerosis (PPMS) is a neurodegenerative disease that interferes with the brain's ability to control the body. There are four main types of MS: relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS. Each type might be mild, moderate, or severe. PPMS is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions.
PPMS can be further characterized at different points in time as either active (with an occasional relapse and/or evidence of new MRI activity) or not active, as well as with progression (evidence of disease worsening on an objective measure of change over time, with or without relapse or new MRI activity) or without progression.
The occurrence and severity of PPMS symptoms vary with each person. Symptoms include headaches, pain in the legs and feet, back pain, muscle spasms, trouble in walking, vision problems, etc. In addition, this condition affects men and women equally.
Some of the companies:
· MedDay Pharma
· MediciNova
· Mapi Pharma
· Brainstorm-Cell Therapeutics
· And Many Others
Drugs Covered:
· GA Depot
· MN-166
· MD1003
· NurOwn
· And Many Others
View Report: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market
Request for free sample report: https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-market
Table of Contents:
1. Key Insights
2. Executive Summary of Primary Progressive Multiple Sclerosis (PPMS)
3. Competitive Intelligence Analysis for Primary Progressive Multiple Sclerosis (PPMS)
4. Primary Progressive Multiple Sclerosis (PPMS): Market Overview at a Glance
4.1. Primary Progressive Multiple Sclerosis (PPMS) Total Market Share (%) Distribution in 2017
4.2. Primary Progressive Multiple Sclerosis (PPMS) Total Market Share (%) Distribution in 2030
5. Primary Progressive Multiple Sclerosis (PPMS): Disease Background and Overview
6. Patient Journey
7. Primary Progressive Multiple Sclerosis (PPMS) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Primary Progressive Multiple Sclerosis (PPMS) Treatment and Management
8.2. Primary Progressive Multiple Sclerosis (PPMS) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Primary Progressive Multiple Sclerosis (PPMS) Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Primary Progressive Multiple Sclerosis (PPMS): Seven Major Market Analysis
13.1. Key Findings
13.2. Primary Progressive Multiple Sclerosis (PPMS) Market Size in 7MM
13.3. Primary Progressive Multiple Sclerosis (PPMS) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Primary Progressive Multiple Sclerosis (PPMS)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for
Browse through our vast repository from here.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/
0 notes
Text
Plaque Psoriasis Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on "Plaque Psoriasis - Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Plaque Psoriasis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Plaque Psoriasis, historical and forecasted epidemiology as well as the Plaque Psoriasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the contents:
· According to National Psoriasis Foundation (NPF), more than 8 million Americans have psoriasis. Plaque psoriasis is the most common form of the disease, affecting 80 percent of those with psoriasis.
· In U.S., the prevalence of Psoriasis is estimated to be 0.6 to 4.8%.
· 125 million people worldwide which is about 2 to 3 percent of the total population have psoriasis, according to the World Psoriasis Day consortium.
· According to Gulbahar S et al., about 90% of psoriasis cases is plaque psoriasis, which is characterized by "plaques", or raised, red areas of skin covered with a silver or white layer of scale.
· Psoriasis is considered equally prevalent in both sexes. However, out of all studies that reported prevalence by sex in Global report of Psoriasis by World Health Organization, some of them indicate that psoriasis is more common in men. This issue needs further investigation.
View Report: https://www.delveinsight.com/report-store/plaque-psoriasis-market
Request for free sample report: https://www.delveinsight.com/sample-request/plaque-psoriasis-market
Scope of the Report
· The report covers the descriptive overview of Plaque Psoriasis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
· Comprehensive insight has been provided into the Plaque Psoriasis epidemiology and treatment in the 7MM
· Additionally, an all-inclusive account of both the current and emerging therapies for Plaque Psoriasis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
· A detailed review of Plaque Psoriasis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
· The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Plaque Psoriasis market
View Report: https://www.delveinsight.com/report-store/plaque-psoriasis-market
Request for free sample report: https://www.delveinsight.com/sample-request/plaque-psoriasis-market
Psoriasis is a common skin condition that speeds up the life cycle of skin cells. It causes cells to build up rapidly on the surface of the skin. The extra skin cells form scales and red patches that are itchy and sometimes painful.
According to National Psoriasis Foundation (NPF), plaque psoriasis is the most common form of psoriasis and appears as raised, red patches covered with a silvery white buildup of dead skin cells. These patches or plaques most often show up on the scalp, knees, elbows and lower back. They are often itchy and painful, and they can crack and bleed.
The characteristic signs and symptoms of psoriasis are small scaly, red bumps. These bumps generally join together into elevated plaques of skin and most often are visible on the elbows, knees, and scalp, although any area of skin can be involved. Frequently, these plaques are quite itchy. Rarely, most of the patient's skin surface is affected.
Some of the Companies:
· Bristol-Myers Squibb
· Dermavant Sciences GmbH
· Arcutis, Inc.
· Avillion LLP
· And Many Others
Drugs Covered:
· TAZORAC
· M1095
· Tapinarof
· BMS-986165
· And Many Others
View Report: https://www.delveinsight.com/report-store/plaque-psoriasis-market
Request for free sample report: https://www.delveinsight.com/sample-request/plaque-psoriasis-market
Table of Contents:
1. Key Insights
2. Executive Summary of Plaque Psoriasis
3. Competitive Intelligence Analysis for Plaque Psoriasis
4. Plaque Psoriasis: Market Overview at a Glance
4.1. Plaque Psoriasis Total Market Share (%) Distribution in 2017
4.2. Plaque Psoriasis Total Market Share (%) Distribution in 2030
5. Plaque Psoriasis: Disease Background and Overview
6. Patient Journey
7. Plaque Psoriasis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Plaque Psoriasis Treatment and Management
8.2. Plaque Psoriasis Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Plaque Psoriasis Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Plaque Psoriasis: Seven Major Market Analysis
13.1. Key Findings
13.2. Plaque Psoriasis Market Size in 7MM
13.3. Plaque Psoriasis Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Plaque Psoriasis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for
Browse through our vast repository from here.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: [email protected] Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/
0 notes